Glucose Testing With GDH-PQQ-Based Products May Cause Falsely High Readings - SFDA
This article was originally published in PharmAsia News
Executive SummaryChina's State FDA released an adverse events notice calling the attention of medical institutions and patients to avoid using GDH-PQQ glucose test products
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.